Status: Recruiting
An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC
This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of Oba01 for injection in patients with DR5 positive LA/mNSCLC.
Participants needed: 35
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Lu ShunUpdated: Dec 20, 2023Locations: 1
Eligibility criteria
Voluntary agreement to provide written informed consent. [+9]
Patient has received previous treatment with DR5 targeted regimen or antibody-MM... [+3]